ARCHIVES

In Brief: Bristol To Drop Angiostatin; Protein Fails To Meet Criteria For Development, Firm Says

This article is from The Cancer Letter archive.

Vol. 25 No. 06 | February 12, 1999

Download PDF Visit The Full Archive

Related Articles

Cancer Control Progress, Challenge Mark ACS Observance

October 18, 1991

Funding opportunities listed.

September 24, 2004

FDA Proposes New Nonclinical Lab Regs

November 26, 1976

ODAC Votes For Approval Of PegIntron For Melanoma, Votrient For Renal Cancer

October 9, 2009

OAM Director Jacobs To Leave; Cites “Conflict with Conscience”

July 15, 1994

Manville Sues U.S. Over “Withheld” Wartime Data

July 22, 1983